ALK has announced top-line results from the Grazax (sublingual allergy immunotherapy tablet) Asthma Prevention (GAP) trial with ALK’s allergy immunotherapy...
Explore the management and treatment limitations
See the diagnosis and learn the pathophysiology
Examine the epidemiology, risk factors, and burden
Discover the emerging treatments and diagnostics
Recently published data from high-impact randomized controlled trials indicate the strong potential of strategies to prevent the development of food allergy in high-risk individuals, but guidance in the United States at present is limited to a policy for only the prevention of peanut allergy, despite other data being available and several other countries advocating early egg and peanut introduction.
Peanut allergy is one of the most common food allergies in children, with increasing prevalence over time. The dual-allergen exposure hypothesis now supports transcutaneous sensitization to peanut as a likely pathophysiologic mechanism for peanut allergy development.
This guidance for the management of patients with hymenoptera venom allergy has been prepared by the Standards of Care Committee (SOCC) of the British Society for Allergy and Clinical Immunology (BSACI).